From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferonalpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer .
RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon . RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity .
GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma .
Sparfosic acid trisodium is a DNA antimetabolite agent and a potent inhibitor of aspartate transcarbamoyl transferase. Aspartate transcarbamoyl transferase catalyzes the second step of de novo pyrimidine biosynthesis. Sparfosic acid trisodium synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
Vidutolimod (CMP-001) is a CpG-A oligodeoxynucleotide. Vidutolimod is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferonalpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
Mipeginterferon alfa-2b is an interferonalpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
Sparfosic acid, a DNA antimetabolite agent, is a potent inhibitor of aspartate transcarbamoyl transferase, the enzyme catalyzing the second step of de novo pyrimidine biosynthesis. Sparfosic acid synergistically enhances the cytotoxicity of a combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN) against human colon cancer cell lines .
GSK2245035 maleate is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 maleate has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 maleate effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 maleate is used for asthma .
MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α(TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line) .
Modakafusp alfa (TAK-573) is a humanized, anti-CD38IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferonalpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A .
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alphainterferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.
MCE offers a unique collection of 344 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.
RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
Modakafusp alfa (TAK-573) is a humanized, anti-CD38IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
Mipeginterferon alfa-2b is an interferonalpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (HEK293, His) contains 166 a.a. (C24-D189), produced in HEK293 cells cells with a C-terminal His-tag.
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Rat (HEK293, Fc) contains 166 a.a. (C24-K189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Mouse (P.pastoris, His) contains 168 a.a. (C24-E189), produced in P. pastoris yeast cells with a C-terminal His-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Mouse (HEK293, His) contains 166 a.a. (C24-E189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Rat (HEK293, His) contains 189 a.a. (M1-E189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 14 (IFNA14), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 14/IFNA14 Protein, Human (His-SUMO) contains 166 a.a. (C24-D189), produced in E. coli cells with a N-terminal His-SUMO tag.
IFN-alpha 10 (IFNA10), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 10/IFNA10 Protein, Human (HEK293, His) contains 189 a.a. (M1-D189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Mouse (HEK293, Fc) contains 189 a.a. (M1-E189), produced in HEK293 cells with a C-terminal hFc-tag.
IFN-alpha 10 (IFNA10), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 10/IFNA10 Protein, Human (HEK293, Fc) contains 166 a.a. (C24-D189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 6 (IFNA6), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 6/IFNA6 Protein, Human (His-Myc) contains 169 a.a. (S21-E189), produced in E. coli cells with a N-terminal His-tag and a C-terminal Myc-tag.
IFN-alpha 6 (IFNA6), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 6/IFNA6 Protein, Human (HEK293, His) contains 169 a.a. (S21-E189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (HEK293, Fc) contains 166 a.a. (C24-D189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Human (sf9, His) contains 189 a.a. (M1-D189), produced in Sf9 insect cells cells with a C-terminal His-tag.
IFN-alpha 14 (IFNA14), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 14/IFNA14 Protein, Mouse (HEK293, Fc) contains 166 a.a. (C24-K189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 14 (IFNA14), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 14/IFNA14 Protein, Mouse (HEK293, His) contains 166 a.a. (C24-K189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Human (HEK293, Fc) contains 168 a.a. (L22-E189), produced in HEK293 cells cells with a N-terminal hFc-tag.
IFN-alpha 5 (IFNA5), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 5/IFNA5 Protein, Human (P.pastoris, His) contains 168 a.a. (L22-E189), produced in P. pastoris yeast cells with a C-terminal His-tag.
IFN-alpha 14 (IFNA14), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 14/IFNA14 Protein, Rhesus Macaque (P.pastoris, His) contains 166 a.a. (C24-D189), produced in P.pastoris yeast cells with a C-terminal His-tag.
IFN-alpha 1a/IFNA1 Protein, produced by macrophages, demonstrates robust antiviral activities. It stimulates essential enzymes—a protein kinase and an oligoadenylate synthetase—contributing to the intricate molecular response that fortifies the host's immune defenses against viral threats. Animal-Free IFN-alpha 1/IFNA13 Protein, Human (His) is the recombinant human-derived animal-FreeIFN-alpha 1a/IFNA1 protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.
IFN-alpha 7 (IFNA7), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 7/IFNA7 Protein, Human (HEK293, Fc) contains 166 a.a. (C24-D189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 7 (IFNA7), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 7/IFNA7 Protein, Human (P.pastoris, His) contains 166 a.a. (C24-D189), produced in P.pastoris yeast cells with a C-terminal His-tag.
IFN-alpha B/IFNA8 Protein, synthesized by macrophages, displays potent antiviral activities. It stimulates the production of essential enzymes—a protein kinase and an oligoadenylate synthetase—that are pivotal in cellular defense against viral infections. IFN-alpha B/IFNA8 Protein, Human (HEK293) is the recombinant human-derived IFN-alpha B/IFNA8 protein, expressed by HEK293 , with tag free.
IFN alpha 1a Protein, synthesized by macrophages, exhibits robust antiviral activities by stimulating key enzymes—a protein kinase and an oligoadenylate synthetase. This orchestrated molecular response enhances the host's immune defenses against viral threats. IFN-alpha 1/IFNA1 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived IFN-alpha 1/IFNA1 protein, expressed by HEK293 , with C-hFc labeled tag.
IFN-alpha B/IFNA8 Protein, synthesized by macrophages, displays potent antiviral activities. It stimulates the production of essential enzymes—a protein kinase and an oligoadenylate synthetase—that are pivotal in cellular defense against viral infections. IFN-alpha B/IFNA8 Protein, Human (HEK293, His) is the recombinant human-derived IFN-alpha B/IFNA8 protein, expressed by HEK293 , with C-His labeled tag.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2/IFNA2 Protein, Rhesus Macaque (P.pastoris) contains 165 a.a. (C24-E188), is produced in yeast strain P. pastoris with tag free.
IFN-alpha B/IFNA8 protein is a member of the alpha/beta interferon family. IFN-alpha B/IFNA8 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived IFN-alpha B/IFNA8 protein, expressed by HEK293 , with C-mFc labeled tag.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2/IFNA2 Protein, Rhesus Macaque (HEK293, His) contains 188 a.a. (M1-E188), is produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2/IFNA2 Protein, Rhesus Macaque (HEK293, Fc) is produced in HEK293 cells with a C-terminal mFc-tag.
IFN-alpha B/IFNA8 protein is a member of the alpha/beta interferon family. IFN-alpha B/IFNA8 Protein, Cynomolgus (HEK293, C-mFc) is the recombinant cynomolgus-derived IFN-alpha B/IFNA8, expressed by HEK293 , with C-mFc labeled tag.
IFN-alpha 1 (IFNA1), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 1 involves in the activation of JAK1 and TYK2 pathway, exerts function by inhibiting viral replication as well as modulating immune response. IFN-alpha 1/IFNA13 Protein, Human (HEK293, His) is produced in HEK293 cells with a C-Terminal His-tag.
IFN-alpha 2/IFNA2 Protein, synthesized by macrophages, exhibits potent antiviral activities. Its interaction with IFNAR2 plays a pivotal role in signaling processes, contributing to the intricate network of antiviral defense mechanisms. IFN-alpha 2/IFNA2 Protein, Mouse is the recombinant mouse-derived IFN-alpha 2/IFNA2 protein, expressed by E. coli, with tag free.
IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFN-alpha/beta R2 Protein, Human (HEK293, His) is a recombinant human IFN-alpha/beta R2 (I27-K243) with C-terminal 6*His tag, which is produced in HEK293 cells.
IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFN-alpha/beta R2 Protein, Human (HEK293, hFc) is a recombinant human IFN-alpha/beta R2 (I27-K243) with C-terminal hFc tag, which is produced in HEK293 cells.
IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFN-alpha/beta R2 Protein, Cynomolgus (HEK293, His) is a recombinant biotinylated cynomolgus IFN-alpha/beta R2 (M1-K243) with C-terminal His tag, which is produced in HEK293 cells.
IFN-alpha 2/IFNA2 Protein, synthesized by macrophages, exhibits potent antiviral activities. Its interaction with IFNAR2 plays a pivotal role in signaling processes, contributing to the intricate network of antiviral defense mechanisms. IFN-alpha 2/IFNA2 Protein, Mouse (His) is the recombinant mouse-derived IFN-alpha 2/IFNA2 protein, expressed by E. coli , with N-6*His labeled tag.
IFN-alpha/beta R2, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFN-alpha/beta R2 forms the heterodimeric receptor with IFNAR1, and binds to type I IFNs. IFN-alpha/beta R2 also interacts with JAK1 and leads to tyrosine phosphorylation of the IFNARs and STAT proteins. Upon activation by these IFNs, IFNAR1 and IFN-alpha/beta R2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFN-alpha/beta R2 Protein, Human (Biotinylated, HEK293, His) is a recombinant biotinylated human IFN-alpha/beta R2 (I27-K243) with C-terminal His tag, which is produced in HEK293 cells.
IFN-α/β R2 protein forms a heterodimer with IFNAR1 and acts as a receptor for type I interferons. After interferon binding, the receptor subunit activates JAK, leading to the phosphorylation of STAT transcription factors. IFN-alpha/beta R2 Protein, Human (HEK293, His, solution) is the recombinant human-derived IFN-alpha/beta R2 protein, expressed by HEK293 , with C-His labeled tag.
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Mouse (HEK293, His) contains 162 a.a. (C25-E186), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 4 (IFNA4), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 4/IFNA4 Protein, Cynomolgus (HEK293, Fc), produced in HEK293 cells with a C-terminal mFc-tag.
IFN-alpha 13 (IFNA13), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 13/IFNA13 Protein, Cynomolgus (HEK293, Fc) contains 166 a.a. (C25-E190), produced in HEK293 cells with a C-terminal hFc-tag.
IFN-alpha 13 (IFNA13), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 13/IFNA13 Protein, Cynomolgus (HEK293, His) contains 166 a.a. (C25-E190), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 13 (IFNA13), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 13/IFNA13 Protein, Mouse (HEK293, Fc) contains 166 a.a. (C24-E189), produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 13 (IFNA13), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 13/IFNA13 Protein, Mouse (HEK293, His) contains 189 a.a. (M1-E189), produced in HEK293 cells with a C-terminal His-tag.
IFN-alpha 13 (IFNA13), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 13/IFNA13 Protein, Mouse (P.pastoris, His) contains 166 a.a. (C24-E189), produced in P.pastoris yeast cells with a C-terminal His-tag.
IFN-omega protein is a member of the alpha/beta interferon family. IFN-omega 1 Protein, Human (HEK293, His) is the recombinant human-derived IFN-omega protein, expressed by HEK293 , with C-His labeled tag.
IFN-omega protein is a member of the alpha/beta interferon family. IFN-omega 1 Protein, Human (HEK293, Fc) is the recombinant human-derived IFN-omega protein, expressed by HEK293 , with N-hFc labeled tag.
IFN alpha 1a Protein, synthesized by macrophages, exhibits robust antiviral activities by stimulating key enzymes—a protein kinase and an oligoadenylate synthetase. This orchestrated molecular response enhances the host's immune defenses against viral threats. Animal-Free IFN alpha 1/IFNA1 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeIFN alpha 1a protein, expressed by E. coli , with N-His labeled tag.This product is for cell culture use only.
B18R protein functions as a potent antagonist against the antiviral effects of host IFN-alpha/beta and key IFN-inducible proteins, such as OAS1 involved in viral RNA degradation. It acts as a soluble IFN-alpha receptor, effectively impeding the interaction between host IFN-alpha and its receptor. The protein's ability to interact with host IFNA1 underscores its role in modulating the host's immune response against viral infections. B18R Protein, Vaccinia virus (HEK293, His) is the recombinant Virus-derived B18R protein, expressed by HEK293 , with C-6*His labeled tag.
IFN-alpha 1/13 (IFNA1), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 1 involves in the activation of JAK1 and TYK2 pathway, exerts function by inhibiting viral replication as well as modulating immune response. IFN-alpha 1b/IFNA13 Protein, Human contains 166 a.a. (C24-D189, A137V), produced in E. coli cells with tag free.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2/IFNA2 Protein, Mouse (P.pastoris) contains 167 a.a. (C24-E190), is produced in yeast strain P. pastoris with tag free.
IFN-alpha 2a, Human, a cytokine primarily produced by macrophages, displays robust antiviral activities. Its interaction with IFNAR2 is pivotal in mediating essential signaling pathways, contributing to intricate defense mechanisms against viral infections. IFN-alpha 2b/IFNA2 Protein, Human (HEK293, Fc) is the recombinant human-derived IFN-alpha 2b/IFNA2 protein, expressed by HEK293 , with C-hFc labeled tag.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2/IFNA2 Protein, Mouse (HEK293, Fc) contains 167 a.a. (C24-E190), is produced in HEK293 cells with a N-terminal hFc-tag.
IFN-alpha 2 (IFNA2), belongs to type I interferon family, is a protein secreted by cells infected by a virus and acting on other cells to inhibit viral infection. IFN-alpha 2 exerts cytotoxic activity against CD8+ T cells and induces CD4+ T cell depletion. IFN-alpha 2b/IFNA2 Protein, Human (P.pastoris) contains 165 a.a., is produced in yeast strain P. pastoris with tag free.
IFN-alpha 13 (IFNA1), belongs to type I interferon family, is produced by macrophages with antiviral activities. IFN-alpha 1 involves in the activation of JAK1 and TYK2 pathway, exerts function by inhibiting viral replication as well as modulating immune response. IFN-alpha 1/IFNA13 Protein, Human (P.pastoris, His) is produced in P.pastoris yeast cells with a C-Terminal His tag.
IFN-omega 1 protein is a member of the alpha/beta interferon family. IFN-omega 1 Protein, Bovine (His-SUMO) is the recombinant bovine-derived IFN-omega 1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Rhesus Macaque (HEK293) is a recombinant rhesus macaque IFNAR1 (M1-K437) without any tag, which is produced in HEK293 cells.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Rhesus Macaque (HEK293, Fc) is a recombinant rhesus macaque IFNAR1 (M1-K437) with a C-terminal hFc tag, which is produced in HEK293 cells.
The IFI27L2A protein critically regulates interferon-induced transcriptional activity, specifically NR4A1, NR4A2, and NR4A3. Its interaction with XPO1 enhances the nuclear export of these receptors, with potential vascular effects on the injury response. IFI27L2A Protein, Mouse (Cell-Free, His) is the recombinant mouse-derived IFI27L2A protein, expressed by E. coli Cell-free , with N-10*His labeled tag.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Mouse (HEK293, His) is a recombinant mouse IFNAR1 (M1-T429) with C-terminal His tag, which is produced in HEK293 cells.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Human (HEK293, Fc) is a recombinant human IFNAR1 (K28-K436) with C-terminal hFc tag, which is produced in HEK293 cells.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Human (HEK293, His) is a recombinant human IFNAR1 (K28-K436) with C-terminal 6*His tag, which is produced in HEK293 cells.
IFNAR1, one of the subunit of IFN-α/β receptor, is a type I IFN receptor. IFNAR1 forms the heterodimeric receptor with IFNAR2. IFNAR1 mediates IFN-induced STAT signaling by interacting with tyrosine kinase 2 (Tyk2). Upon activation by these IFNs, IFNAR1 and IFNAR2 undergo a conformational change to promote a cascade of downstream signaling events, including the phosphorylation of Tyk2 and JAK1, STAT1 and STAT2. IFNAR1 Protein, Cynomolgus (HEK293, His) is a recombinant Cynomolgus IFNAR1 (A25-K437) with C-terminal 6*His tag, which is produced in HEK293 cells.
IFN-gamma R1 (CD119), one of the subunit of IFN-gamma receptor, is a receptor for IFN-gamma. IFN-gamma R1 forms the functional receptor with IFN-gamma R2. Upon binding with IFN-gamma, IFN-gamma R1 and IFN-gamma R2 oligomerize and transphosphorylate. Then, JAK1 and JAK2 are phosphorylated and activated, and STAT1 is recruited to the receptor complex. Phosphorylated STAT1 translocates to the nucleus, where it regulates the expression of IFN-responsive genes (e.g. CD54). IFN-gamma R1/CD119 Protein, Mouse (HEK293, His) is a recombinant mouse IFN-gamma R1 with C-terminal 6*His tag, which is produced in HEK293 cells.
IFN-gamma R1 (CD119), one of the subunit of IFN-gamma receptor, is a receptor for IFN-gamma. IFN-gamma R1 forms the functional receptor with IFN-gamma R2. Upon binding with IFN-gamma, IFN-gamma R1 and IFN-gamma R2 oligomerize and transphosphorylate. Then, JAK1 and JAK2 are phosphorylated and activated, and STAT1 is recruited to the receptor complex. Phosphorylated STAT1 translocates to the nucleus, where it regulates the expression of IFN-responsive genes (e.g. CD54). IFN-gamma R1/CD119 Protein, Rat (HEK293, Fc) is a recombinant mouse IFN-gamma R1 (M1-S241) with C-terminal hFc tag, which is produced in HEK293 cells.
IFN-gamma R1 (CD119), one of the subunit of IFN-gamma receptor, is a receptor for IFN-gamma. IFN-gamma R1 forms the functional receptor with IFN-gamma R2. Upon binding with IFN-gamma, IFN-gamma R1 and IFN-gamma R2 oligomerize and transphosphorylate. Then, JAK1 and JAK2 are phosphorylated and activated, and STAT1 is recruited to the receptor complex. Phosphorylated STAT1 translocates to the nucleus, where it regulates the expression of IFN-responsive genes (e.g. CD54). IFN-gamma R1/CD119 Protein, Human (228a.a, HEK293, His) is a recombinant human IFN-gamma R1 (E18-G245) with C-terminal 6*His tag, which is produced in HEK293 cells.
IFN-gamma R1 (CD119), one of the subunit of IFN-gamma receptor, is a receptor for IFN-gamma. IFN-gamma R1 forms the functional receptor with IFN-gamma R2. Upon binding with IFN-gamma,IFN-gamma R1 and IFN-gamma R2 oligomerize and transphosphorylate. Then, JAK1 and JAK2 are phosphorylated and activated, and STAT1 is recruited to the receptor complex. Phosphorylated STAT1 translocates to the nucleus, where it regulates the expression of IFN-responsive genes (e.g. CD54). IFN-gamma R1/CD119 Protein, Human (HEK293, His, solution) is a recombinant human IFN-gamma R1 (E18-G245) with C-terminal 6*His tag, which is produced in HEK293 cells.
IFN-γ R1/CD119 is an important receptor subunit of interferon γ/INFG that activates effector immune cells and enhances antigen presentation, contributing to antibacterial, antiviral, and antitumor responses. It cooperates with IFNGR2 to form a functional receptor. IFN-gamma R1/CD119 Protein, Human (HEK293, His-Flag) is the recombinant human-derived IFN-gamma R1/CD119 protein, expressed by HEK293 , with C-6*His, C-Flag labeled tag.
The CXCL11 protein selectively attracts interleukin-activated T cells and induces calcium release in these cells. Its binding to CXCR3 suggests a complex role in T cell chemotaxis and may be important in CNS diseases involving T cell recruitment. I-TAC/CXCL11 Protein, Mouse is the recombinant mouse-derived CXCL11 protein, expressed by E. coli , with tag free.
The CXCL11 protein selectively attracts interleukin-activated T cells and induces calcium release in these cells. Its binding to CXCR3 suggests a complex role in T cell chemotaxis and may be important in CNS diseases involving T cell recruitment. Animal-Free I-TAC/CXCL11 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeI-TAC/CXCL11 protein, expressed by E. coli , with N-His labeled tag. This product is for cell culture use only.
IFNAR1; IFNAR; interferonalpha/beta receptor 1; IFN-R-1; IFN-alpha/beta receptor 1; Cytokine receptor class-II member 1; Cytokine receptor family 2 member 1; CRF2-1; Type I interferon receptor 1
WB, IP
Human
Interferon alpha/beta Receptor 1 Antibody (YA3112) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3112), targeting Interferon alpha/beta Receptor 1, with a predicted molecular weight of 64 kDa (observed band size: 110-130 kDa). Interferon alpha/beta Receptor 1 Antibody (YA3112) can be used for WB, IP experiment in human background.
EIF2AK2; PKR; PRKR; interferon-induced; double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2; eIF-2A protein kinase 2; interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein k
WB, IHC-P, IP, ChIP
Human
Phospho-PKR (Thr446) Antibody (YA1026) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1026), targeting Phospho-PKR (Thr446), with a predicted molecular weight of 62 kDa (observed band size: 62 kDa). Phospho-PKR (Thr446) Antibody (YA1026) can be used for WB, IHC-P, IP, ChIP experiment in human background.
EIF2AK2; PKR; PRKR; interferon-induced; double-stranded RNA-activated protein kinase; Eukaryotic translation initiation factor 2-alpha kinase 2; eIF-2A protein kinase 2; interferon-inducible RNA-dependent protein kinase; P1/eIF-2A protein k
WB
Human
Phospho-PKR (Thr451) Antibody (YA1025) is a non-conjugated IgG antibody, targeting Phospho-PKR (Thr451), with a predicted molecular weight of 62 kDa (observed band size: 74 kDa). Phospho-PKR (Thr451) Antibody (YA1025) can be used for WB experiment in human background.
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferonalpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
Vidutolimod (CMP-001) is a CpG-A oligodeoxynucleotide. Vidutolimod is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferonalpha (IFNα) release, leading to a cascade of anti-tumor immune effects.
Inquiry Online
Your information is safe with us. * Required Fields.
